Diabetes Drugs and Cardioprotection: 8 Questions on Key Trials

Your daily dose of clinical news you may have missed.

Patrick Moriarty, MD, from the University of Kansas Medical Center, discusses the role of Lp(a) as a risk factor for cardiovascular disease and the phase 3 trials of a potential treatment.

Sanofi is the third key insulin maker to announce reductions in the cost of its products, joining other giants Eli Lilly and Co and Novo Nordisk.

Podcast: Hypertension expert Daichi Shimbo, MD, offers tips on putting SPRINT results into clinical practice.

Young children using a hybrid closed-loop insulin delivery system spent 12% more time within their target blood glucose range than those who received standard care, according to new research.

Youth at the upper range of normal weight had a 26% higher risk of developing hypertension than those in the lower range of normal weight, according to a new study.